Skip to main content

CORRECTION article

Front. Oncol., 14 January 2022
Sec. Gynecological Oncology
This article is part of the Research Topic Familial Cancer in China: From Detection to Screening and Management View all 7 articles

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Jun Li Jun Li 1,2Sile Han Sile Han 2Cuiyun Zhang Cuiyun Zhang 1,2Yanlin Luo Yanlin Luo 3Li Wang Li Wang 3Ping Wang Ping Wang 4Yi Wang Yi Wang 5Qingxin Xia Qingxin Xia 5Xiaoyan Wang Xiaoyan Wang 1,2Bing Wei Bing Wei 1,2Jie Ma Jie Ma 1,2Hongle Li Hongle Li 1,2*Yongjun Guo Yongjun Guo 1,2*
  • 1 Henan Key Laboratory of Molecular Pathology, China
  • 2 Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, China
  • 3 Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, China
  • 4 Department of Pathophysiology, School of Basic Medical Science, Zhengzhou University, China
  • 5 Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, China

A Corrigendum on:
Identification of BRCA1: c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

by Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H and Guo Y (2021). Front. Oncol. 11:655709. doi: 10.3389/fonc.2021.655709

In the original article, we neglected to include the funder National Natural Science Foundation of China, 81802779 to Jun Li; Henan Provincial Health Commission, SBGJ202002020 to Jun Li; and Henan Science and Technology Project, 212102310675 to Jun Li.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: BRCA1/2, haplotype analysis, ovarian cancer, founder mutation, Chinese

Citation: Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H and Guo Y (2022) Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients. Front. Oncol. 11:840551. doi: 10.3389/fonc.2021.840551

Received: 21 December 2021; Accepted: 22 December 2021;
Published: 14 January 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Li, Han, Zhang, Luo, Wang, Wang, Wang, Xia, Wang, Wei, Ma, Li and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yongjun Guo, guoyongjun@zzu.edu.cn; Hongle Li, llhl73@163.com

These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.